A&G Pharmaceutical and South Korean biopharmaceutical company Celltrion have entered into an agreement for clinical production of A&G's theranostic monoclonal antibody for the treatment of cancer. Celltrion will perform bioprocess development, scale-up, and cGMP manufacturing and provide all clinical materials to support toxicology studies as well as phase I and phase II US clinical studies on A&G's anti-GP88 monoclonal antibody. Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=9C81CF28-2508-4AD7-8A73-61715E44CFE4)